Victor Grifols Deu
Director/Board Member at GRIFOLS, S.A.
Net worth: 131 654 $ as of 2024-03-30
Profile
Currently, Victor Grifols Deu occupies the position of Joint Chief Executive Officer & Executive Director at Grifols SA. Mr. Deu is also on the board of Araclon Biotech SL. He received an undergraduate degree from Institut Químic De Sarrià and an MBA from UCD Michael Smurfit Graduate School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GRIFOLS, S.A. CLASS A
0.00% | 2022-12-30 | 14,620 ( 0.00% ) | 131 654 $ | 2024-03-30 |
Victor Grifols Deu active positions
| Companies | Position | Start |
|---|---|---|
| GRIFOLS, S.A. | Director/Board Member | 2016-05-29 |
Araclon Biotech SL
 Araclon Biotech SL Miscellaneous Commercial ServicesCommercial Services Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain. | Director/Board Member | - |
Training of Victor Grifols Deu
| UCD Michael Smurfit Graduate School of Business | Graduate Degree |
| Institut Químic De Sarrià | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GRIFOLS, S.A. | Health Technology |
| Private companies | 1 |
|---|---|
Araclon Biotech SL
Araclon Biotech SL Miscellaneous Commercial ServicesCommercial Services Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain. | Commercial Services |
- Stock Market
- Insiders
- Victor Grifols Deu
